These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 14747046

  • 1. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ, Small EJ.
    Urology; 2003 Dec 29; 62 Suppl 1():87-94. PubMed ID: 14747046
    [Abstract] [Full Text] [Related]

  • 2. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B.
    Urology; 2003 Dec 29; 62 Suppl 1():79-86. PubMed ID: 14747045
    [Abstract] [Full Text] [Related]

  • 3. Hormone therapy in advanced prostate cancer.
    Forster TH, Stoffel F, Gasser TC.
    Front Radiat Ther Oncol; 2002 Dec 29; 36():49-65. PubMed ID: 11842755
    [No Abstract] [Full Text] [Related]

  • 4. Endocrine therapy of prostate cancer.
    Bare RL, Torti FM.
    Cancer Treat Res; 1998 Dec 29; 94():69-87. PubMed ID: 9587683
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 29; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.
    Urologia; 2010 Nov 29; 77(2):71-83. PubMed ID: 20890863
    [Abstract] [Full Text] [Related]

  • 12. The androgen receptor for the radiation oncologist.
    Quero L, Rozet F, Beuzeboc P, Hennequin C.
    Cancer Radiother; 2015 May 29; 19(3):220-7. PubMed ID: 25921704
    [Abstract] [Full Text] [Related]

  • 13. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM.
    Front Radiat Ther Oncol; 2002 May 29; 36():66-71. PubMed ID: 11842756
    [No Abstract] [Full Text] [Related]

  • 14. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
    Bolla M, de Reijke TM, Zurlo A, Collette L.
    Front Radiat Ther Oncol; 2002 May 29; 36():81-6. PubMed ID: 11842758
    [No Abstract] [Full Text] [Related]

  • 15. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS.
    J Urol; 2006 Jan 29; 175(1):27-34. PubMed ID: 16406864
    [Abstract] [Full Text] [Related]

  • 16. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
    Gomella LG, Zeltser I, Valicenti RK.
    Urology; 2003 Dec 29; 62 Suppl 1():46-54. PubMed ID: 14747041
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.
    Expert Opin Investig Drugs; 2006 Jul 29; 15(7):795-804. PubMed ID: 16787142
    [Abstract] [Full Text] [Related]

  • 18. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Jul 29; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 19. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K.
    Cancer; 1999 Apr 15; 85(8):1822-7. PubMed ID: 10223578
    [Abstract] [Full Text] [Related]

  • 20. The evolving role of hormone therapy in advanced prostate cancer.
    Dreicer R.
    Cleve Clin J Med; 2000 Oct 15; 67(10):720-2, 725-6. PubMed ID: 11060958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.